Effect of 5-HT2A receptor antagonism on levels of D2/3 receptor occupancy and adverse behavioral side-effects induced by haloperidol: a SPECT imaging study in the rat
Open Access
- 14 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Translational Psychiatry
- Vol. 11 (1), 1-13
- https://doi.org/10.1038/s41398-020-01179-5
Abstract
Several studies suggested that 5-HT2A receptor (5-HT2AR) blockade may provide a more favorable efficacy and side-effect profile to antipsychotic treatment. We hypothesized that a combined haloperidol (a D2/3 receptor (D2/3R) antagonist) and MDL-100,907 (a 5-HT2AR antagonist) treatment would reverse the side effects and the neurochemical alterations induced by haloperidol alone and would potentialize its efficacy. We thus chronically treated male Mdr1a knock-out rats with several doses of haloperidol alone or in combination with a saturating dose of a MDL-100,907. Receptor occupancy at clinically relevant levels was validated with a dual-radiotracer in-vivo SPECT imaging of D2/3R and 5-HT2AR occupancy. Experimental tests of efficacy (dizocilpine-disrupted prepulse inhibition (PPI) of the startle reflex) and side effects (catalepsy, vacuous chewing movements) were performed. Finally, a second dual-radiotracer in-vivo SPECT scan assessed the neurochemical changes induced by the chronic treatments. Chronic haloperidol failed to reverse PPI disruption induced by dizocilpine, whilst administration of MDL-100,907 along with haloperidol was associated with a reversal of the effect of dizocilpine. Haloperidol at 0.5 mg/kg/day and at 1 mg/kg/day induced catalepsy that was significantly alleviated (by ~50%) by co-treatment with MDL-100,907 but only at 0.5 mg/kg/day dose of haloperidol. Chronic haloperidol treatment, event at doses as low as 0.1 mg/kg/day induced a significant upregulation of the D2/3R in the striatum (by over 40% in the nucleus accumbens and over 20% in the caudate-putamen nuclei), that was not reversed by MDL-100,907. Finally, an upregulation of 5-HT2AR after chronic haloperidol treatment at a moderate dose only (0.25 mg/kg/day) was demonstrated in frontal cortical regions and the ventral tegmental area. Overall, a partial contribution of a 5-HT2AR antagonism to the efficacy and side-effect profile of antipsychotic agents is suggested.Funding Information
- Jean et Madeleine Vachoux Foundation Greek National Scholarship Foundation
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (310030_156829)
- Geneva Neuroscience Center Swiss Association for Alzheimer’s Research
This publication has 91 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Modulation of firing and synaptic transmission of serotonergic neurons by intrinsic G protein-coupled receptors and ion channelsFrontiers in Integrative Neuroscience, 2013
- HDAC2 regulates atypical antipsychotic responses through the modulation of mGlu2 promoter activityNature Neuroscience, 2012
- Persistent effects of chronic clozapine on the cellular and behavioral responses to LSD in micePsychopharmacology, 2012
- Functional crosstalk and heteromerization of serotonin 5-HT2A and dopamine D2 receptorsNeuropharmacology, 2011
- Antagonist Functional Selectivity: 5-HT2A Serotonin Receptor Antagonists Differentially Regulate 5-HT2A Receptor Protein Level In VivoThe Journal of pharmacology and experimental therapeutics, 2011
- Antipsychotic-induced vacuous chewing movements and extrapyramidal side effects are highly heritable in miceThe Pharmacogenomics Journal, 2010
- The principled control of false positives in neuroimagingSocial Cognitive and Affective Neuroscience, 2009
- Pyramidal Neurons in Rat Prefrontal Cortex Projecting to Ventral Tegmental Area and Dorsal Raphe Nucleus Express 5-HT2A ReceptorsCerebral Cortex, 2008
- Realistic expectations of prepulse inhibition in translational models for schizophrenia researchPsychopharmacology, 2008